Cargando…
New Therapies to Correct the Cystic Fibrosis Basic Defect
Rare diseases affect 400 million individuals worldwide and cause significant morbidity and mortality. Finding solutions for rare diseases can be very challenging for physicians and researchers. Cystic fibrosis (CF), a genetic, autosomal recessive, multisystemic, life-limiting disease does not escape...
Autores principales: | Bergeron, Christelle, Cantin, André M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227161/ https://www.ncbi.nlm.nih.gov/pubmed/34201249 http://dx.doi.org/10.3390/ijms22126193 |
Ejemplares similares
-
The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients
por: Morin, Caroline, et al.
Publicado: (2018) -
Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
por: Cantin, André M.
Publicado: (2019) -
CLCA4 variants determine the manifestation of the cystic fibrosis basic defect in the intestine
por: Kolbe, Ernst-Wolfgang, et al.
Publicado: (2013) -
The P2X7 Receptor in Cystic Fibrosis Monocytes: Linking CFTR Deficiency to Inflammation
por: Cantin, André M.
Publicado: (2022) -
A review of cystic fibrosis: Basic and clinical aspects
por: Chen, Qionghua, et al.
Publicado: (2021)